Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.59 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.55 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.45 |
| ▸ | CPT2 | P23786 | 4/20 | 0.44 |
| ▸ | CPT1A | P50416 | 4/20 | 0.44 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32677484 | 0.89 | ALDH1A1 (0.52) | DPP4KMT2AALDH1A1ENPP2CPT2 | |
| SCHEMBL7167933 | 0.84 | CPT1A (0.60) | DPP4SPHK2SPHK1KMT2ACPT2 | |
| SCHEMBL11481661 | 0.84 | CPT1A (0.60) | DPP4SPHK2SPHK1KMT2ACPT2 | |
| SCHEMBL3187180 | 0.78 | ALDH1A1 (0.61) | KMT2AALDH1A1CPT2CPT1A | |
| SCHEMBL3187156 | 0.78 | ALDH1A1 (0.61) | KMT2AALDH1A1CPT2CPT1A | |
| SCHEMBL5741958 | 0.75 | KMT2A (0.65) | KMT2AALDH1A1CPT2CPT1A | |
| SCHEMBL5741952 | 0.75 | KMT2A (0.65) | KMT2AALDH1A1CPT2CPT1A | |
| SCHEMBL32677456 | 0.75 | EPHX2 (0.43) | DPP4SPHK2SPHK1SCN9AENPP2 | |
| Ammonia Solution, Strong SCHEMBL32677501 | 0.74 | EPHX2 (0.42) | DPP4SPHK2SPHK1SCN9AENPP2 | |
| SCHEMBL1241528 | 0.74 | PDK2 (0.42) | SPHK2SPHK1KMT2ASCN9ACPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224599-A1 | PYRROLIDINE-BASED GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250326741-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326741-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | DPP4 115/4885SPHK2 3517/4885SPHK1 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.